Cadila Healthcare gets DCGI nod to conduct phase III trials for two-dose Covid vaccine

The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20.

  • Updated On Oct 5, 2021 at 05:16 PM IST
Read by: 100 Industry Professionals
Reader Image Read by 100 Industry Professionals
NEW DELHI: Drug firm Cadila Healthcare on Tuesday said it has received permission from the Indian drug regulator for conducting phase III trials for its two-dose Covid-19 vaccine ZyCoV-D.

The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20.

The company has "... got the permission for conduct of phase III trials for two-dose Covid vaccine," Cadila Healthcare said in a regulatory filing.

Earlier in August, in a filing to BSE, Cadila Healthcare had said that it plans to seek approval for the two dose regimen of the vaccine. It had also mentioned that the company plans to manufacture 10-12 crore doses of ZyCoV-D annually.

Advt
Shares of Cadila Healthcare Ltd were trading at Rs 563.95 per scrip on BSE, up 0.29 percent from their previous close.
  • Published On Oct 5, 2021 at 05:16 PM IST
Be the first one to comment.
Comment Now

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles
Scan to download App